Phyllis McKiernan, MSN, APN, OCN, Blood & Marrow Transplant Program, John Theurer Cancer Center explains factors that go into choosing an iron chelation therapy for a patient with myelodisplastic syndrome (MDS) experiencing transfusion-related iron overload.
A promising CD19-directed chimeric antigen (CAR) T-cell therapy, Lisocabtagene maraleucel (JCAR017; liso-cel), may result in durable remissions among patients with high-risk diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma.
Patients with relapsed/refractory heavily pretreated multiple myeloma could live for an extra progression-free year with the use of the anti-BCMA CAR T-cell therapy bb2121.
Next-generation sequencing (NGS) in metastatic non–small cell lung cancer (NSCLC) can save Center for Medicare and Medicaid Services (CMS) payers $1.4 million to $2.1 million.
Patients with head and neck cancer (HNC) who tracked their symptoms using the CYCORE (CYberinfrastructure for COmparative Effectiveness REsearch) system’s mobile and sensor technology experienced reduced symptom severity compared with those who received standard care, according to results of a large randomized trial.
Cancer immunotherapies are a promising development, but taking care of patients who are using these drugs can be a challenge for oncology nurses.
Oncology nurses play an important role in educating patients with chronic lymphocytic leukemia (CLL) about the adverse effects (AEs) associated with ibrutinib (Imbruvica) treatment.
A symptom assessment app used at home may empower education and self-management among patients, and help with clinician communication.
In patients with advanced breast cancer, oncology nurses play a key role in outcomes by providing education and supporting adherence to a treatment regimen.
While the use of nivolumab (Opdivo) plus ipilimumab (Yervoy) shows promise for a subgroup of patients with metastatic colorectal cancer (mCRC), 32% still experienced a treatment-related adverse effect.
Estimates find that 10-64% of patients experience financial hardships related to the cost of medical care.
A clinically meaningful overall response rate was experienced by people with chronic graft versus host disease.
When a woman learns she carries a BRCA gene mutation—and thus, in her lifetime, faces an 87% risk of developing breast cancer and a 63% risk of getting ovarian cancer—she has a difficult decision-making process ahead of her. One nurse created an easy-to-understand guide that explains all options and their pros and cons, for use by oncology nurses working with BRCA mutation carriers who do not have cancer—previvors.
“While there is substantial research documenting the psychosocial characteristics in cancer patients and local caregivers to date, none have focused solely on the comparison of patients with their distance caregivers,” the researchers stated in an abstract presented by AnnMarie Papik, B.S.
As the Food and Drug Administration continues to approve additional indications for olaparib (Lynparza), health care providers and caregivers should be aware of the potential adverse effects (AEs) associated with treatment.
When given before a stem cell transplant, busulfan plus melphalan, improved progression-free survival in patients with myeloma, but came with some extra adverse events.
Researchers recommended that survivors of younger-adult breast cancer learn and watch for the signs and symptoms of heart problems or failure, such as shortness of breath and fatigue, and always go to their follow-up appointments, where health care practitioners may keep tabs on their heart health.
Adding patient engagement strategies can help to enhance the research agenda for oncology nursing.
How are patients with cancer triaged at key points throughout their journeys? Who helps them understand their diagnoses or treatments and prioritizes what to do next? Who pulls in the resources needed to make sure patients get what they need as expeditiously as possible?
Surveillance of potentially cancerous skin lesions is key in early detection and treatment of the disease, which vastly improves outcomes.
A recent survey showed that nurses are willing to be trained in how to offer an affirmative healthcare experience to individuals who identify as lesbian, gay, bisexual, or transgender; however, only 4.7% were able to demonstrate knowledge of this patient community.
As part of a larger study, nurses found it is important for AYAs to remain physically active during and after cancer treatment.
Cancer treatment should not solely rely on the oncologist, says Rasheda Persinger-Adams, NP, MSN, OCN.
When it comes to patient-nurse relationships in cancer care, "You've got to be there for them," says Jill Schwartz Gomez, RN, CCRP.
Training staff and educating patients can increase compliance and prepare for potential adverse events.
A multidisciplinary team approach may help in seeing optimal patient outcomes following the administration of a powerful drug combination for patients with relapsed/refractory chronic lymphocytic leukemia (CLL).
Ribociclib (Kisqali), a targeted CDK4/6 inhibitor, is gaining traction in the treatment of hormone receptor–positive, human epidermal growth factor receptor (HER) 2–negative advanced breast cancer, and nurses and patients need to be educated about its possible adverse effects (AEs).
Patient-reported outcomes allowed oncology nurses to better support patients’ needs.
Not only are PARP inhibitors proving to be an efficacious treatment for patients with metastatic breast cancer, but they're also improving quality of life, too.
